SIAP
CRSP icon

Sterling Investment Advisors (Pennsylvania)’s CRISPR Therapeutics CRSP Stock Holding History

Sterling Investment Advisors (Pennsylvania)’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-600
Closed -$36K – 209
2022
Q2 		$36K Hold
600
– – 0.01% 256
2022
Q1 		$38K Hold
600
– – 0.01% 283
2021
Q4 		$45K Buy
600
+200
+50% +$17.5K 0.01% 265
2021
Q3 		$45K Hold
400
– – 0.01% 260
2021
Q2 		$65K Buy
+400
New +$48.6K 0.02% 234

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania)'s CRSP Position: Q3 2022 in Review

Sterling Investment Advisors (Pennsylvania) sold out of CRISPR Therapeutics (CRSP) in Q3 2022, closing a stake of 600 shares — an estimated $36K sold.

Sterling Investment Advisors (Pennsylvania) first reported a position in CRSP in Q2 2021 and held it in 5 quarters. The position peaked at $65K in Q2 2021. 436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

  • Sterling Investment Advisors (Pennsylvania) reported no remaining CRISPR Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Sterling Investment Advisors (Pennsylvania) sold 600 CRISPR Therapeutics shares in Q3 2022, an estimated $36K.
  • Sterling Investment Advisors (Pennsylvania) first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 5 quarters.
  • Sterling Investment Advisors (Pennsylvania)'s CRISPR Therapeutics position peaked at $65K in Q2 2021.
  • 436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q3 2022, filed 3 Nov 2022.